GSK walks away from Ionis antisense drugs
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals’ experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.
Read More
Tag: hepatitis B virus
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
